ABBV AbbVie Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
05:12
Sep 01
Sep 01
Author notes healthcare stocks are setting up in a strong uptrend and lists XLV's top holdings.
Author notes healthcare stocks are setting up in a strong uptrend and lists XLV's top holdings as a watchlist, not an explicit position.
LOW
02:57
Aug 20
Aug 20
Piper Sandler raises its price target on AbbVie to 303 dollars from 298 dollars.
Piper Sandler raises its price target on AbbVie to 303 dollars from 298 dollars, reflecting a modestly positive analyst adjustment.
11:28
Aug 17
Aug 17
A news wire reports a broad list of price target increases across dozens of stocks from various.
A news wire reports a broad list of price target increases across dozens of stocks from various analysts, with no directional commentary or personal market views expressed.
10:56
Aug 13
Aug 13
Wolfe Research, JPMorgan, Citizens, Citi, Jefferies, RBC, Wells Fargo, Cantor Fitzgerald.
Wolfe Research, JPMorgan, Citizens, Citi, Jefferies, RBC, Wells Fargo, Cantor Fitzgerald, Roth/MKM, UBS, BofA, and Nomura issue multiple analyst upgrades and downgrades with various price target changes across a broad set of stocks.
16:37
Aug 10
Aug 10
Long AbbVie, healthcare winner up 17%
Author discloses an ongoing long position in AbbVie within a healthcare/biotech sleeve; currently up 17%+ and held as a core winner in the portfolio.
MED
15:42
Aug 09
Aug 09
Lupron demand seen lifted by fertility spotlight
Buy ABBV as Lupron, used in fertility protocols, stands to benefit from increased public attention on fertility treatments driven by AOC's egg-freezing news; very thin catalyst.
LOW
13:07
Aug 08
Aug 08
The tweet lists large-cap pharma companies with high short interest.
The tweet lists large-cap pharma companies with high short interest, citing a Financial Times article, but offers no personal position or directional call.
LOW
16:35
Aug 04
Aug 04
AbbVie is seeking to raise at least eight billion dollars from an investment-grade bond.
AbbVie is seeking to raise at least eight billion dollars from an investment-grade bond offering to fund part of its acquisition of Apogee.
15:58
Aug 03
Aug 03
AbbVie's Q2 results and raised guidance are reported factually.
AbbVie's Q2 results and raised guidance are reported factually, but the author's neutral hold rating is not a directional trade call.
09:58
Aug 03
Aug 03
A news wire reports a broad list of price target raises across dozens of stocks from multiple.
A news wire reports a broad list of price target raises across dozens of stocks from multiple analysts, with no directional commentary or personal market views expressed.
22:18
Jul 31
Jul 31
AbbVie's lowered outlook due to acquisition costs is reported as a factual earnings update.
AbbVie's lowered outlook due to acquisition costs is reported as a factual earnings update, not a directional trade call.
LOW
15:10
Jul 31
Jul 31
AbbVie reported second quarter profit and sales that beat Wall Street expectations.
AbbVie reported second quarter profit and sales that beat Wall Street expectations, driven by strong immunology and neuroscience demand and Botox recovery signs.
13:00
Jul 31
Jul 31
Management raised full-year revenue and EPS guidance, indicating sustained strong momentum across key growth products, partly offset by anticipated (but non-core) near-term dilution from the Apogee acquisition.
HIGH
12:39
Jul 31
Jul 31
US pre-market movers show Apple falling on weak China sales and guidance.
US pre-market movers show Apple falling on weak China sales and guidance, Amazon rising on faster AWS growth, with mixed earnings across energy, healthcare, and tech stocks.
11:54
Jul 31
Jul 31
AbbVie reports Q2 2026 earnings with adjusted EPS and revenue beating estimates while narrowing.
AbbVie reports Q2 2026 earnings with adjusted EPS and revenue beating estimates while narrowing its full-year adjusted EPS guidance range.
11:49
Jul 31
Jul 31
AbbVie reports second quarter earnings with adjusted EPS and revenue both beating analyst.
AbbVie reports second quarter earnings with adjusted EPS and revenue both beating analyst estimates while Skyrizi and Rinvoq sales also exceeded expectations.
11:47
Jul 31
Jul 31
AbbVie reports Q2 adjusted EPS and revenue above estimates while trimming full-year adjusted.
AbbVie reports Q2 adjusted EPS and revenue above estimates while trimming full-year adjusted EPS outlook to 14 cents versus consensus of 14 dollars.
11:35
Jul 29
Jul 29
Barclays, Jefferies, RBC, JP Morgan, and other firms raised price targets on dozens of stocks.
Barclays, Jefferies, RBC, JP Morgan, and other firms raised price targets on dozens of stocks including ABBV, KO, and F in a broad round of analyst upgrades.
14:32
Jul 28
Jul 28
Author notes KO and ABBV as late cycle rotation names but does not state a personal position.
Author notes KO and ABBV as late cycle rotation names but does not state a personal position or forward call, only referencing a sector trend.
LOW
16:52
Jul 27
Jul 27
Author notes ABBV's pattern of consecutive M&A deals; watching for follow-on deal activity.
LOW
22:34
Jul 26
Jul 26
Peak earnings season begins with 177 S&P 500 companies reporting Q2 results this week.
Peak earnings season begins with 177 S&P 500 companies reporting Q2 results this week, including mega caps like Apple, Amazon, and Microsoft.
23:58
Jul 15
Jul 15
Buy AbbVie, fantastic performance
AbbVie is performing fabulously, not just a spin-off, and should be bought.
MED
08:30
Jul 15
Jul 15
JNJ management acknowledges that AbbVie's Skyrizi is maintaining share in IBD/psoriasis despite Tremfya's strong growth, indicating ongoing competitive pressure in the IL-23 market.
HIGH
22:58
Jul 13
Jul 13
Hold ABBV as a defensive healthcare rotation play entered from the lows.
Hold ABBV as a defensive healthcare rotation play entered from the lows; author is rotating into non-tech sectors during an expected ~70-day late-cycle rotation away from technology.
MED
01:49
Jul 08
Jul 08
Named as a likely acquirer of ERAS; merger docs from APGE deal show AbbVie sought expedited.
Named as a likely acquirer of ERAS; merger docs from APGE deal show AbbVie sought expedited timeline to free BD bandwidth for additional deals.
MED
01:21
Jul 03
Jul 03
Author describes a balanced core portfolio rebalanced in June 2026 that has outperformed.
Author describes a balanced core portfolio rebalanced in June 2026 that has outperformed the S&P 500, but the tweet is a retrospective performance update and general advice to stay balanced, not a fresh trade call.
23:56
Jul 02
Jul 02
The author analyzes merger document details between AbbVie and Apogee.
The author analyzes merger document details between AbbVie and Apogee, noting AbbVie's ultimatum and competitive interest in the AtD space, but does not state a personal position or forward call.
LOW
23:24
Jul 02
Jul 02
The tweet details the merger timeline between AbbVie and Apogee with no author position.
The tweet details the merger timeline between AbbVie and Apogee with no author position, noting that the atopic dermatitis space remains of interest to biopharma.
LOW
15:54
Jul 02
Jul 02
Long these names as part of a balanced portfolio rebalanced on 6/15 to rotate out of tech into.
Long these names as part of a balanced portfolio rebalanced on 6/15 to rotate out of tech into healthcare, financials, energy, and defensives, outperforming SPY by 4x.
MED
14:00
Jul 01
Jul 01
Reports Goldman Sachs increasing position in $ABBV as part of hedging with healthcare.
MED
About ABBV Analyst Coverage
Buzzberg tracks ABBV (AbbVie Inc.) across 19 sources. 13 bullish vs 0 bearish calls from 24 analysts. Sentiment: predominantly bullish (16%). 81 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: asklivermore, FirstSquawk, DeItaone.